Advancements in medical device and ancillary technologies are leading to significant improvements in the new combination therapies available to patients. Adam Lambert of Pharmatech Associates explains how the importance of getting buy-in from regulatory authorities early in the development process is critical to establish meaningful specifications. Read the article on Pharmtech’s website.